Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
| 155.64 Delayed Data As of Jan 27 |  +0.09 / +0.06%Today’s Change | 125.36 Today|||52-Week Range 169.98 | -2.30% Year-to-Date |
Latest JAZZ News | Press Releases
| Nepsis Inc. Buys 2, Sells 3 in 4th Quarter Jan 25 / GuruFocus News - Paid Partner Content | 2 Promising New Growth Stocks to Watch in 2023 Jan 23 / MotleyFool.com - Paid Partner Content |
| Strength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength? Jan 25 / Zacks.com - Paid Partner Content | Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival Jan 20 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 155.55 |
| Today’s open | 155.20 |
| Day’s range | 153.63 - 156.76 |
| Volume | 15,368 |
| Average volume (3 months) | 550,646 |
| Market cap | $9.9B |
Data as of 3:59pm ET, 01/27/2023
Growth & Valuation
| Earnings growth (last year) | -228.94% |
| Earnings growth (this year) | +9.01% |
| Earnings growth (next 5 years) | +7.04% |
| Revenue growth (last year) | +30.91% |
| P/E ratio | NM |
| Price/Sales | 2.46 |
| Price/Book | 2.44 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CTLTCatalent Inc | +1.38 | +2.64% |
| RDYDr Reddy's Laborator... | 0.00 | 0.00% |
| SRPTSarepta Therapeutics... | -0.02 | -0.02% |
| RGENRepligen Corp | 0.00 | 0.00% |
Data as of 4:00pm ET, 01/27/2023
Financials
| Next reporting date | February 28, 2023 |
| EPS forecast (this quarter) | $4.47 |
| Annual revenue (last year) | $3.1B |
| Annual profit (last year) | -$329.7M |
| Net profit margin | -10.65% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Dublin, Dublin |
Forecasts
